City of Hope scientists have developed and tested the first chimeric antigen receptor therapy using chlorotoxin, a component of scorpion venom, to direct T cells to target brain tumor cells, according to a preclinical study published March 4 in Science Translational Medicine. The institution has also opened the first in-human clinical trial to use the therapy.
When President Donald Trump on Feb. 3 signed H.R.7148, a package funding most of the federal government through FY26, many in oncology released a long-held sigh of relief.
